-
Je něco špatně v tomto záznamu ?
In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus
A. Böhm, V. Lauko, K. Dostalova, I. Balanova, I. Varga, B. Bezak, N. Jajcay, R. Moravcik, L. Lazurova, P. Slezak, V. Mojto, M. Kollarova, K. Petrikova, K. Danova, M. Zeman
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články
Grantová podpora
VEGA 1/0563/21
Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- MeSH
- adenosindifosfát farmakologie MeSH
- agregace trombocytů fyziologie MeSH
- diabetes mellitus 2. typu * farmakoterapie MeSH
- infarkt myokardu * MeSH
- inhibitory agregace trombocytů farmakologie terapeutické užití MeSH
- lidé MeSH
- melatonin * farmakologie terapeutické užití MeSH
- trombocyty fyziologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: The incidence of acute myocardial infarctions (AMI) shows circadian variation typically peaking during morning hours with a decline at night. However, this variation does not occur in patients with diabetes mellitus (DM). The night's decline of AMI may be partially explained by melatonin-related platelet inhibition. Whether this effect is absent in diabetic patients is unknown. The aim was to study the effect of melatonin on in-vitro platelet aggregation in healthy individuals and patients with type 2 DM. METHODS: Platelet aggregation was measured in blood samples from healthy individuals (n = 15) and type 2 DM patients (n = 15) using multiple electrode aggregometry. Adenosine diphosphate (ADP), arachidonic acid (ASPI) and thrombin (TRAP) were used as agonists. Aggregability for each subject was tested after adding melatonin in two concentrations. RESULTS: In healthy individuals, melatonin inhibited platelet aggregation in both higher (10-5 M) and lower concentrations (10-9 M) induced by ADP, ASPI, and TRAP (p < 0.001, p = 0.002, p = 0.029, respectively). In DM patients, melatonin did not affect platelet aggregation in both concentrations induced by ADP, ASPI, and TRAP. Melatonin decreased platelet aggregation induced by ADP, ASPI, and TRAP significantly more in healthy individuals compared to patients with DM. (p = 0.005, p = 0.045 and p = 0.048, respectively). CONCLUSION: Platelet aggregation was inhibited by melatonin in healthy individuals. In-vitro antiplatelet effect of melatonin in type 2 DM patients is significantly attenuated.
Cardio Integra s r o Bratislava Slovakia
Faculty of Medicine Comenius University in Bratislava Bratislava Slovakia
National Institute of Cardiovascular Diseases Bratislava Slovakia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000558
- 003
- CZ-PrNML
- 005
- 20240213093246.0
- 007
- ta
- 008
- 240109s2023 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s40618-023-02102-7 $2 doi
- 035 __
- $a (PubMed)37148530
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Böhm, A $u Premedix Academy, Medená 18, 81102, Bratislava, Slovakia. allan.bohm@premedix.org $u 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava, University Hospital Bratislava, Bratislava, Slovakia. allan.bohm@premedix.org $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia. allan.bohm@premedix.org $1 https://orcid.org/0000000272373223 $7 xx0264215
- 245 10
- $a In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus / $c A. Böhm, V. Lauko, K. Dostalova, I. Balanova, I. Varga, B. Bezak, N. Jajcay, R. Moravcik, L. Lazurova, P. Slezak, V. Mojto, M. Kollarova, K. Petrikova, K. Danova, M. Zeman
- 520 9_
- $a PURPOSE: The incidence of acute myocardial infarctions (AMI) shows circadian variation typically peaking during morning hours with a decline at night. However, this variation does not occur in patients with diabetes mellitus (DM). The night's decline of AMI may be partially explained by melatonin-related platelet inhibition. Whether this effect is absent in diabetic patients is unknown. The aim was to study the effect of melatonin on in-vitro platelet aggregation in healthy individuals and patients with type 2 DM. METHODS: Platelet aggregation was measured in blood samples from healthy individuals (n = 15) and type 2 DM patients (n = 15) using multiple electrode aggregometry. Adenosine diphosphate (ADP), arachidonic acid (ASPI) and thrombin (TRAP) were used as agonists. Aggregability for each subject was tested after adding melatonin in two concentrations. RESULTS: In healthy individuals, melatonin inhibited platelet aggregation in both higher (10-5 M) and lower concentrations (10-9 M) induced by ADP, ASPI, and TRAP (p < 0.001, p = 0.002, p = 0.029, respectively). In DM patients, melatonin did not affect platelet aggregation in both concentrations induced by ADP, ASPI, and TRAP. Melatonin decreased platelet aggregation induced by ADP, ASPI, and TRAP significantly more in healthy individuals compared to patients with DM. (p = 0.005, p = 0.045 and p = 0.048, respectively). CONCLUSION: Platelet aggregation was inhibited by melatonin in healthy individuals. In-vitro antiplatelet effect of melatonin in type 2 DM patients is significantly attenuated.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory agregace trombocytů $x farmakologie $x terapeutické užití $7 D010975
- 650 12
- $a melatonin $x farmakologie $x terapeutické užití $7 D008550
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
- 650 _2
- $a agregace trombocytů $x fyziologie $7 D010974
- 650 _2
- $a trombocyty $x fyziologie $7 D001792
- 650 12
- $a infarkt myokardu $7 D009203
- 650 _2
- $a adenosindifosfát $x farmakologie $7 D000244
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lauko, V $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia
- 700 1_
- $a Dostalova, K $u Slovak Medical University, Bratislava, Slovakia
- 700 1_
- $a Balanova, I $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia
- 700 1_
- $a Varga, I $u Cardio-Integra s.r.o., Bratislava, Slovakia
- 700 1_
- $a Bezak, B $u Premedix Academy, Medená 18, 81102, Bratislava, Slovakia $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia $u Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
- 700 1_
- $a Jajcay, N $u Premedix Academy, Medená 18, 81102, Bratislava, Slovakia $u Department of Complex Systems, Institute of Computer Science, Czech Academy of Sciences, Prague 8, Czech Republic
- 700 1_
- $a Moravcik, R $u Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
- 700 1_
- $a Lazurova, L $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia
- 700 1_
- $a Slezak, P $u Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
- 700 1_
- $a Mojto, V $u Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
- 700 1_
- $a Kollarova, M $u Premedix Academy, Medená 18, 81102, Bratislava, Slovakia $u Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
- 700 1_
- $a Petrikova, K $u Premedix Academy, Medená 18, 81102, Bratislava, Slovakia
- 700 1_
- $a Danova, K $u National Institute of Cardiovascular Diseases, Bratislava, Slovakia
- 700 1_
- $a Zeman, M $u Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
- 773 0_
- $w MED00002652 $t Journal of endocrinological investigation $x 1720-8386 $g Roč. 46, č. 12 (2023), s. 2493-2500
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37148530 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093243 $b ABA008
- 999 __
- $a ok $b bmc $g 2049302 $s 1210252
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 46 $c 12 $d 2493-2500 $e 20230506 $i 1720-8386 $m Journal of endocrinological investigation $n J Endocrinol Invest $x MED00002652
- GRA __
- $a VEGA 1/0563/21 $p Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- LZP __
- $a Pubmed-20240109
